Anti-Human VEGF (Bevacizumab) - Biotin
Code | Size | Price |
---|
LEI-LT401-100ug | 100 ug | £345.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Antibody Isotype: Human IgG1κ
Antibody Clonality: Monoclonal
Antibody Clone: A4.6.1
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Flow Cytometry
Shipping:
2-8°C
Storage:
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.
Further Information
Antigen Distribution:
VEGF is widely expressed in the thyroid, prostate, and various other tissues.
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Biotin
Format:
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Recombinant human VEGF.
Long Description:
Bevacizumab is a monoclonal antibody that specifically recognizes vascular endothelial growth factor (VEGF). VEGF is a growth factor that participates in angiogenesis, vasculogenesis, and endothelial cell growth. It facilitates endothelial cell proliferation, cell migration, and the permeabilization of blood vessels. In addition, VEGF inhibits apoptosis. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the regression of tumor vascularization, normalization of remaining tumor vasculature, and inhibition of the formation of new tumor vasculature, thus inhibiting tumor growth.1 Anti-Human VEGF (Bevacizumab) utilizes the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research projects.
NCBI Gene:
7422
Target:
VEGF
References
1. Pazdur, R. et al. (2018) Clin Cancer Res. 24(18):4365-70.